Key Findings
Top Five Players Account For Over 35% Share of the Exosome Diagnostics and Therapeutics Market
The exosome diagnostics and therapeutics market remains a fragmented landscape. Top five companies collectively represent a significant share in the exosome diagnostics and therapeutics market. These companies include Thermo Fisher Inc., Malvern Instruments, Miltenyi Biotec, Exosome Sciences and Exosome Diagnostics that account for over 35 percent revenue share in exosome diagnostics and therapeutics market.
Market presence of these tier 1 companies is mainly in the United States. Key participants in the exosome diagnostics and therapeutics market are mainly involved in new product launches and acquisitions. In 2017, Exosome Diagnostics launched MedOncAlyzer 170, its biopsy pan-cancer panel that circulates tumor DNA in a single assay. In addition, these players are also involved in collaborations and partnerships with local vendors in a bid to enhance their distribution network.
Favorable Support from Regulatory Bodies to Accelerate Growth
Increasing support from governments and regulatory bodies with respect to funding and research grants continues to influence the growth of exosome diagnostics and therapeutics market. Formulation of policies and subsidy provisions by various governments have encouraged research and development activities in the exosome diagnostics and therapeutics space.
Regulatory bodies have been encouraging development or up gradation of therapeutic devices for efficient treatment of chronic diseases. For instance, Food and Drug Administration (FDA) launched Breakthrough Devices Program in December 2017 to facilitate effective diagnosis of life-threatening diseases. Companies in the exosome diagnostics and therapeutics space are benefitted as they are able to enhance their therapeutic base. Aethlon Medical Inc., under the Breakthrough Devices Program, obtained EAP (Expedited Access Pathway) to push its Hemopurifier system as an effective treatment against fatal viruses.
Exosome Diagnostics and Therapeutics in Drug Delivery to Fight Chronic Conditions
Exosome diagnostics and therapeutics market is largely influenced by the growing potential of exosomes as carriers of functional RNA and proteins. The demand for exosome diagnostics and therapeutics is expected to increase at a significant pace owing to their use in drug delivery field. Several exosome agents are in pipeline that are being evaluated for chronic diseases. For instance, Capricor Therapeutics is assessing exosomes produced by CDCs for treating inflammatory conditions.
In addition, exosome diagnostics and therapeutics companies are focused on tapping exosome diagnostics and therapeutics potential to reduce metastasis. For instance, Aethlon Medical is developing HER2osome device. Use of exosome diagnostics and therapeutics as a potential agent in drug delivery is expected to fuel the growth of exosome diagnostics and therapeutics market in the coming years.
Venture Financing – New Trend in the Exosome Diagnostics and Therapeutics Market
Venture capital firms are investing in the exosome diagnostics and therapeutics market. Growing investments in the exosome diagnostics and therapeutics space are supporting upcoming start-ups in developing their exosome diagnostics and therapeutics platforms. For instance, Google Ventures supported a funding of US$ 45.4 million for exosome diagnostics and therapeutics company – Evox Therapeutics. This trend is likely to offer potential avenues for exosome diagnostics and therapeutics companies in turn supporting the future of exosome diagnostics and therapeutics as a major biotech breakthrough.
Competitive Landscape
Companies involved in the exosome diagnostics and therapeutics market are focusing on launching new exosome diagnostics and therapeutics products. For instance, Exosome Diagnostics Inc., has introduced bladder cancer surveillance panel, an addition in its exosome diagnostics and therapeutics portfolio.
Companies are launching tools and making investments to support exosome diagnostics and therapeutics research. Lonza has carried out huge investments via the acquisition of HansaBiomed Life Sciences in May 2017. Exosome diagnostics and therapeutics companies are also rolling out on conducting new clinical trials by achieving regulatory approvals.
For instance, in December 2017, Capricor Therapeutics Inc., achieved clearance from FDA for new clinical trial of CAP-1002. Likewise, in 2018, Aegle gained clearance for its exosome diagnostics and therapeutics clinical trials in humans.
Companies are also involved in acquisitions to enhance their footprint in exosome diagnostics and therapeutics space. For instance, recently, Bio-Techne Corporation acquired Exosome Diagnostics to enhance its leadership in the exosome diagnostics and therapeutics market, particularly in on-invasive liquid biopsy space.
World's Most Profilic Intelligence Engine
Get Access To The World's Largest Market Research Database. Ngage with a revolutionary intelligence engine that scale and pricing that flexes as per your needs
Sign Up Now
Market segmentation
By Product Type
- Instrument
- Software
- Reagents and Kits
By Application
- Diagnostics
- Therapeutics
By End User
- Hospitals
- Cancer Institutes
- Diagnostic Centres
- Others
By Region
- North America
- Latin America
- Eastern Europe
- Western Europe
- Asia Pacific excluding Japan
- Japan
- Middle East and Africa
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports